1. Jerkeman M, Johansson B, Akerman M, Cavallin-Stahl E, Kristoffersson U, Mitelman F. Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol 1999 Mar;62(3):184-90.

2.Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaloy S, Sundstrom C, Akerman M. CHOP versus MACOP-B in aggressive lymphoma–a Nordic Lymphoma Group randomised trial. Ann Oncol 1999 Sep;10(9):1079-86.

3.Rodriguez-Catarino M, Jerkeman M, Ahlstrom H, Glimelius B, Hagberg H. Residual mass in aggressive lymphoma–does size, measured by computed tomography, influence clinical outcome? Acta Oncol 2000;39:485-9.

4. Amini RM, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E and Glimelius B. Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin’s disease: the Swedish National Health Care Programme experience. Eur J Haematol 2000;65:379-89

5. Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial Med Oncol 2001;18:85-94.

6. Osby E, Taube A, Cavallin-Stahl E, Hagberg H, Bjorkholm M. Reproducibility of tumor response e-valuation in patients with high-grade malignant non-Hodgkin’s lymphoma. Med Oncol 2001;18:137-40.

7. Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin’s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP Br J Cancer 2001;84:303-7.

8. Amini R-M, Glimelius B, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Enblad G. A population-based study of the outcome for patients with first relapse of Hodgkin’s lymphoma. Eur J Haematol 2002;68:225-232.

9. Jerkeman M, Aman P, Cavallin-Stahl E, Torlakovic E, Akerman M, Mitelman F, Fioretos T. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma–a Nordic Lymphoma Group study. Int J Oncol 2002 Jan;20:161-5.

10. Goldkuhl C, Ekman T, Wiklund T, Telhaug R. Age-adjusted chemotherapy for primary central-nervous system lymphoma–a pilot study. Acta Oncol 2002;41(1):29-35.

11. Kimby E. Beyond immunochemotherapy: combinations of rituximab with cytokines IFN-α2a and G-CSF. Sem in Oncology 2002; 29: 7-10.

12.Hagenbeek A, Czuczman M, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Rituximab therapy for indolent non-Hodgkin’s lymphoma. Anti-Cancer Drugs 2002;13(Suppl 2):S11-S17

13. Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Bjorkholm M. CHOP is superior to CNOP in elderly patients with aggressive
List of publications, NLG 1999-August 2008 2
lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group Randomized trial. Blood 2003;101(10):3840-8.

14. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study. Clin Cancer Res. 2003;9:722-8.

15. Molin D, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Glimelius B. Early and intermediate stage Hodgkin’s lymphoma – report from the Swedish National Care Programme. Eur J Haematol 2003;70:172-80.

16. Andersen NS, Pedersen, Elonen E et al for the Nordic Lymphoma Group. Primary Treatment with autologous stem cell transplantation in Mantle Cell Lymphoma. Outcome related to remission pretransplant but not to tumour cell contamination of the autograft. Eur J Haematol 2003;71:73-80.

17. Donna Weber, Steven P. Treon, Christos Emmanouilides, Andrew R. Branagan, John C. Byrd, Joan Blade, and Eva Kimby. Uniform Response Criteria in Waldenstrom’s Macroglobulinemia. Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003:30:127-31.

18. Jantunen E, d’Amore F. Stem cell transplantation for peripheral T-cell lymphomas. Leuk Lymphoma 2004;45:441-6.

19. Jerkemann M, Andersson H, Dictor M, Kvaløj S, Åkerman M, Cavallin-Ståhl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Ann Hematol. 2004;83:414-9

20. Jerkeman M, Leppä S, Kvaløy S and Holte H. ICE (ifosfamide, carboplatin, etoposide) as second- line chemotherapy in relapsed or primary progressive aggressive lymphoma – the Nordic Lymphoma Group experience.. Eur J Haematol 2004 Sep;73(3):179-82.

21. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van t Veer M, Vranovsky A, Holte H, Van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A for EORTC Lymphoma Group, HOVON, 3NCIC CTG Hematology Group (Canada), BNLI, Australasian Leukaemia and Lymphoma Group, Nordic Lymphoma Group, EORTC Data Center. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 2006;108:3295-301.

22. Björkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H,Cavallin-Ståhl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007 Jun;18(6):1085-9.

23. Eva Kimby, Jesper Jurlander, Christian Geisler, Hans Hagberg, Harald Holte, Tuula Lehtinen, Björn Östenstad, Mads Hansen, Anders Österborg, Ola Lindén, and Christer Sundström, on behalf of the Nordic Lymphoma Group: Long-Term Molecular Remissions in Patients With Indolent Lymphoma Treated With Rituximab as a Single Agent or in Combination With Interferon α-2a: A Randomized Phase II Study From the Nordic Lymphoma Group. Leuk Lymphoma 2008;49:102-12.
List of publications, NLG 1999-August 2008 3

24. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordstrom M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundstrom C, Langholm R, Delabie J,Karjalainen-Lindsberg ML, Brown P, Elonen E. Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A non-randomized phase-II multicenter study by the Nordic Lymphoma Group. Blood 2008 2008;112:2687-93

25. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzen, GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmér B, Geisler CH for the Nordic Lymphoma Group. Preemptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009 Aug 3